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Many AIDS vaccine candidates under development may elicit immune responses similar to those observed in and used
to screen human immunodeficiency virus type 1 (HIV-1)-infected individuals. Therefore, it is important to develop vaccine
candidates that incorporate antigenic markers and allow vaccinees to be distinguished from HIV-1 infectees. To this end, we
introduced a series of mutations into and in the vicinity of the major immunodominant region (MIR) of gp41 (residues
598–609), a domain recognized by almost all HIV-1 infectees, and evaluated whether HIV-1-like particles incorporating such
mutant glycoproteins could be expressed in mammalian cells. Results indicated that although up to three consecutive amino
acids could be replaced within MIR without significantly affecting particle formation or gp160 processing, deletions within
MIR impaired envelope processing. Replacement of HIV-1 MIR by part or most of the corresponding domain from other
lentiviruses markedly decreased or abolished gp160 processing. Synthetic peptides corresponding to a mutated MIR
incorporating three amino acid replacements were not recognized by a panel of sera from HIV-1 infectees, suggesting that
HIV-1-like particles with this type of mutation represent potential candidate vaccines that could allow vaccinees to be
distinguished from HIV-1 infectees. © 1999 Academic Press1
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aINTRODUCTION
Development of an effective vaccine against human
mmunodeficiency virus type 1 (HIV-1), the etiologic
gent of AIDS (Barre-Sinoussi et al., 1983; Gallo et al.,
984; Popovic et al., 1984), represents a key priority for
he control of the global AIDS pandemic. It has been
stimated that by the year 2000 more than 40 million
ndividuals will be infected with HIV-1 worldwide (World
ealth Organization, 1996). Several major obstacles have
ampered the development of a successful candidate
IV-1 vaccine. These include the lack of understanding
f the correlates of protective immunity against the virus
Haynes, 1996; Haynes et al., 1996; Heilman and Balti-
ore, 1998; Letvin, 1998), the extraordinary genetic di-
ersity of HIV-1 (Myers et al., 1990), viral persistence as
atent proviral DNA (Chun et al., 1997), and lack of an
ppropriate animal model despite the usefulness of non-
uman primates (Desrosiers, 1995; Heeney, 1996; Huls-
otte et al., 1998; Johnson, 1996; Letvin, 1998; Warren and
evinson, 1995).
Although several vaccine approaches against HIV-1
ave been evaluated, most of them have targeted the
iral envelope (env) glycoprotein (Burke, 1995; Dolin,
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438995; Fast and Walker, 1993; Graham and Wright, 1995;
aynes, 1996; Heilman and Baltimore, 1998; Letvin, 1998;
cElrath et al., 1997; Rovinski and Klein, 1994). The focus
n this particular antigen stems from several consider-
tions. First, the env glycoprotein is the major surface
ntigen expressed by the virus on HIV-1-infected cells. It
s initially synthesized as a glycosylated polyprotein pre-
ursor (gp160) in the endoplasmic reticulum before mi-
rating to the Golgi complex where it is cleaved by a host
rotease to generate the mature surface glycoprotein,
p120, and a transmembrane glycoprotein, gp41 (Earl et
l., 1991; Freed and Martin, 1995; Willey et al., 1988).
hese two subunits oligomerize during viral assembly
nd mediate virus entry into target cells (Burton, 1997;
arl et al., 1990; Freed and Martin, 1995; Kowalski et al.,
987; McDougal et al., 1991; Otteken et al., 1996). Sec-
nd, the initial interaction between HIV-1 and target cells
s known to involve a specific high-affinity binding be-
ween gp120 and the cell surface molecule CD4 (McDou-
al et al., 1991). This is followed by conformational
hanges in gp120 and gp41 and interactions with pro-
eins of the chemokine receptor family, which recently
ere identified as coreceptors for HIV-1 (Alkhatib et al.,
996; Choe et al., 1996; Deng et al., 1996; Dragic et al.,
996; Feng et al., 1996; Simmons et al., 1996). Third, the
nv glycoprotein is directly implicated in cellular tropism
nd pathogenesis (Levy, 1993; Putney et al., 1993; So-
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439ANTIGENICALLY MARKED NONINFECTIOUS HIV-1-LIKE PARTICLESroski et al., 1993). Finally, the HIV-1 env glycoprotein is
major target of neutralization and CTL immune re-
ponses (Burke, 1995; Burton, 1997; Dolin, 1995; Graham
nd Wright, 1995; Heilman and Baltimore, 1998; Letvin,
998; McElrath et al., 1997; Putney et al., 1993; Sattentau,
996; Sodroski et al., 1993; Wilson et al., 1998).
In addition to providing effective immunity against
IV-1, an ideal candidate HIV-1 vaccine should allow one
o distinguish vaccinees from infectees. This is particu-
arly important for a new generation of more complex
IDS vaccine candidates that incorporate several viral
ntigens. We previously demonstrated the feasibility of
roducing noninfectious HIV-1-like particles as potential
andidate immunogens for the development of an HIV-1
accine (Haynes et al., 1991; Rovinski et al., 1992, 1995).
hese virus-like particles incorporate most of the HIV-1
tructural proteins, including the transmembrane glyco-
rotein gp41, which, like the transmembrane glycoprotein
f other lentiviruses, contains a highly conserved immu-
odominant domain (Gallaher et al., 1989). Since sera
rom nearly all HIV-1 infectees recognize a peptide cor-
esponding to this domain (Gnann et al., 1987; Norrby et
l., 1987), it might be necessary to develop HIV-1-like
articles that incorporate antigenic markers in order to
istinguish vaccinees from infectees. Therefore, in this
tudy we sought to determine whether such antigenic
arkers could be introduced into HIV-1-like particles by
utating the immunodominant domain within the gp41
lycoprotein. We show that several amino acid substitu-
ions can be introduced between the two conserved
ysteine residues present in the immunodominant do-
ain of HIV-1 without impairing the processing of the
recursor env glycoprotein and the incorporation of the
utated mature glycoproteins into secreted, noninfec-
ious HIV-1-like particles. We also report on the identifi-
ation of a specific locus within gp41 that can serve as a
arget for insertion of antigenic markers that may allow
ne to distinguish vaccinees from infectees.
RESULTS
Recombinant plasmid vectors used to study the ex-
ression of antigenically marked HIV-1-like particles.
everal plasmid vectors were constructed to study the
xpression of noninfectious virus-like particles contain-
ng mutated gp41 env proteins. These mutations were
ntroduced within or in the vicinity of the major immuno-
ominant region (MIR) of gp41 (residues 598–609) in an
ffort to destroy the peptide epitope that is recognized by
irtually all HIV-1-infected individuals (Gnann et al., 1987;
orrby et al., 1987). We previously used the inducible
uman metallothionein promoter (MT) to produce immu-
ogenic HIV-like particles in stably engineered primate
ell lines (Haynes et al., 1991; Rovinski et al., 1992, 1995).
he expression vector pMTHIVd25 was further modified
o construct p83-19 (Fig. 1) (Persson et al., 1998) by (1)ntroducing point mutations into an area of the gag gene,
hich encodes the Cys-His box, which has been shown
o play a role in viral RNA packaging (Dorfman et al.,
993; Gorelick et al., 1990); (2) deleting most of the pol
ene, eliminating expression of reverse transcriptase
nd integrase; and (3) replacing the gp120LAI coding
equences with those of gp120MN. The p83-19 plasmid
as further mutated to introduce modifications in the
NA encoding the gp41 MIR in order to produce HIV-1-
ike particles with gp41 proteins containing deletions,
mino acid replacements, and heterologous peptide
ragments from the MIR domain of other lentiviruses. All
he modifications within or in the vicinity of MIR are
llustrated in Fig. 2; these included various deletions,
onservative and nonconservative amino acid replace-
ents, and replacement of HIV-1 MIR with the cognate
egion from visna or feline immunodeficiency virus (FIV).
Expression of HIV-1-like particles with mutated gp41
nvelope glycoproteins. To determine whether the muta-
ions within gp41 MIR affected the processing and/or
ncorporation of the precursor envelope glycoproteins
nto virus-like particles, COS-7 cells were transfected
ith the various recombinant expression vectors, and
articles pelleted from the culture supernatants were
nalyzed by immunoblotting 48 h after transfection. Env
FIG. 1. Construction of expression plasmid p83-19 and modified
lasmids encoding mutated env glycoproteins. The nucleotide and
mino acid numbering used throughout for HIV-1 was designated by
yers et al. (1990). Plasmid p83-19 was derived from plasmid
MTHIVd25 (Rovinski et al., 1992) and was engineered to incorporate
everal mutations to enhance safety (Persson et al., 1998). These
utations include (1) deletion of both HIV-1 LTRs and of a 25-bp DNA
ragment (nucleotides 753 to 777; LAI sequence) containing viral RNA
ackaging sequences (Aldovini and Young, 1990; Lever et al., 1989); (2)
wo point mutations in the gag gene to modify the Cys-His motifs, which
lso play a role in RNA packaging (Dorfman et al., 1993; Gorelick et al.,
990); and (3) deletion of most of the pol gene to eliminate reverse
ranscriptase and integrase enzyme activities. In this vector, the tran-
cription of the HIV-1 coding sequences is regulated by the inducible
uman MT IIa promoter and an SV40 polyadenylation sequence. A
eries of p83-19-based expression vectors encoding env glycoproteins
ith mutations within or in the vicinity of the MIR of gp41 (residues
98–609) was generated by oligonucleotide-directed site-specific mu-
agenesis using a commercially available kit (Amersham Canada Ltd.,
akville, Ontario, Canada). To this end, a 2.7-kbp SalI–BamHI DNA
ragment from p83-19 containing the entire env gene coding sequence
as subcloned into M13mp18 prior to mutagenesis. All mutations were
onfirmed by DNA sequencing on a Prism ABI 377 automated ABI
equencer.
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440 ROVINSKI ET AL.roteins were visualized using anti-gp120 or anti-gp41
onoclonal antibodies. As shown in Fig. 3, the deletion
f amino acids 594–600, which flank the MIR, did not
ffect the synthesis of precursor gp160 glycoproteins
Fig. 3A); a protein band in the control (Mock) sample,
ith apparent molecular mass of ;170 kDa, which non-
pecifically reacted with the anti-gp120 antibody, is
ometimes observed in Western blots (see also Fig. 4C).
owever, this deletion impaired the processing of gp160
ince no or very faint protein bands with apparent mo-
ecular weights consistent with those of native gp120
nd gp41 were observed in pelleted HIV-like particles
Figs. 3A and 3B, respectively). The antibody reactive
FIG. 2. Amino acid sequence alignment comparing the wild-type and
he modified residues are indicated, and deletions are represented b
FIG. 3. Immunoblot analysis of env glycoproteins incorporating de-
etions within MIR and associated with pelleted HIV-1-like particles.
onkey COS-7 cells were transfected with wild-type and mutant plas-
ids, and pelleted virus-like particles were prepared as previously
escribed (Rovinski et al., 1992). Viral proteins were then separated by
DS–PAGE and analyzed by immunoblotting using either the neutral-
zing anti-HIV-1MN gp120 monoclonal antibody 50.1 or the anti-gp41
ouse monoclonal antibody secreted by the Chessie 8 hybridoma.
lectrophoretic mobilities of native gp120, gp41, and unprocessed
p160 env glycoproteins are indicated. Mock denotes pelleted material
btained from mock-transfected COS-7 cells.and that migrates below gp120 (;100–110 kDa) is not a
egradation product of gp120 or a partially glycosylated
nv protein. This band represents an integrin that is
resent at high levels on plasma membranes from mon-
ey kidney cells, and we have observed the same inte-
rin associated with other non-HIV vaccine preparations
ngineered in monkey kidney cells (unpublished data).
he two deletions affecting the MIR domain (D601–609
nd D603–609) also impaired envelope processing.
hen the immunoblots shown in Fig. 3 were scanned by
ensitometry to determine the relative levels of gp160
nd gp120, the results indicated that approximately 50%
f the gp160 produced by the control expression vector
as processed while no processing was observed for
he gp160 expressed from the mutated vectors. These
esults suggest that deletions within and in the proximal
icinity of the MIR domain have a detrimental effect on
he processing of the envelope glycoprotein precursor
hat is expressed in association with HIV-1 virus-like
articles. This effect is not due to decreased gp160
ynthesis in the transfected cells since the very small
ariations detected by densitometry in the amounts of
recursor glycoproteins in transfected COS-7 cells could
ot account for the lack of gp120 in the virus-like parti-
les expressed from the mutated vectors.
We also investigated whether amino acid substitutions
ithin MIR had any effect on envelope processing or
ncorporation into HIV-1-like particles. Several amino
cid substitutions were introduced between the two con-
erved cysteine residues of MIR (residues 603 and 609,
espectively) without severely affecting synthesis and
rocessing of the precursor glycoprotein. For example,
eplacement of the positively charged Lys residue at
osition 606 with either positively or negatively charged
t HIV-1 MIR domains expressed by the indicated plasmid constructs.
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441ANTIGENICALLY MARKED NONINFECTIOUS HIV-1-LIKE PARTICLESrg and Glu amino acids, respectively, did not impair
nvelope processing (Fig. 4). The degree of processing,
etermined by densitometric analysis of a scan of the
mmunoblots shown in Fig. 4, was similar to that ob-
erved with the wild-type construct (73–80% processing).
ikewise, replacement of the Gly residue at position 605
ith Ala did not affect gp160 processing. Furthermore,
ike the wild-type p83-19 control sample and the three
ubstitutions mentioned above, protein bands with ap-
arent molecular weights consistent with those of native
p120 and gp41 were observed in pelleted HIV-1-like
articles isolated from supernatants of COS-7 cells
ransfected with constructs expressing envelope glyco-
roteins with mutations affecting amino acids 604–606
Figs. 4A and 4B, respectively). Replacement of residues
GK with GAR (604–606 SGK/GAR), AFR (604–606 SGK/
FR), GAE (604–606 SGK/GAE), or TLE (604–606 SGK/
LE) did not significantly affect processing of the precur-
or gp160 glycoprotein or envelope incorporation into
IV-1-like particles (62–78% processing), although less
p41 seemed to be associated with virus-like particles
xpressed from the AFR mutant construct. However,
hen the entire domain between the two conserved Cys
esidues was modified (amino acids 604–608), the pro-
essing of the precursor glycoprotein was slightly im-
aired (28–31% processing) in two of three mutant con-
tructs (Fig. 4; compare 604–608 SGKLI/TGRIL to 604–
08 SGKLI/GAEMA or 604–608 SGKLI/ELDKWAS) as
videnced by the decreased reactivity of the anti-gp120
nd anti-gp41 antibodies with gp120 and gp41, respec-
FIG. 4. Immunoblot analysis of env glycoproteins incorporating am
articles. Monkey COS-7 cells were transfected with wild-type and mut
he legend to Fig. 3.ively. Therefore, these results indicate that the locus
efined by amino acids 604–606 within MIR can tolerate
everal amino acid substitutions without severely affect-
ng gp160 processing or incorporation of gp120 and
utated gp41 envelope glycoproteins and their incorpo-
ation into HIV-1-like particles.
When the Trp residue at position 601 was modified, it
as observed that its substitution with Ala (601 W/A)
mpaired envelope processing. However, substitution
ith another aromatic amino acid (601 W/Y) did not alter
p160 processing or incorporation of gp120 and mutated
p41 into HIV-1-like particles (Fig. 4). Therefore, these
esults suggest a critical role for this Trp residue within
IR in the processing of the precursor env glycoprotein.
A previous report (Pancino et al., 1995) demonstrated
hat a chimeric FIV glycoprotein containing amino acids
04–608 from HIV-1 instead of the corresponding FIV
esidues, which are delineated by the two Cys residues
ithin the MIR domain of FIV, was correctly processed
nd maintained the capacity to induce syncytium forma-
ion. Hence, it was of interest to evaluate whether re-
lacement of amino acids 604–608 within HIV-1 MIR with
he corresponding immunodominant region of other len-
iviruses would impair the processing of the envelope
recursors and/or their incorporation into HIV-like parti-
les. To this end, amino acids 604–608 from HIV-1 were
eplaced with the corresponding domain of FIV (604–608
GKL/NQNQFF) or Visna (604–608 SGKL/WHYQHY). Al-
hough not completely impaired, the processing of pre-
ursor glycoprotein was affected by the two substitutions
id substitutions within MIR and associated with pelleted HIV-1-like
smids, and pelleted virus-like particles were analyzed as described inino ac
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442 ROVINSKI ET AL.s shown by the decreased intensity of the gp120 and
p41 bands (Figs. 4C and 4D, respectively). The degree
f gp160 processing varied between 18 and 33%, respec-
ively. Interestingly, when, in addition to amino acids
04–608, residues 598–601 of HIV-1 are also replaced
ith the corresponding amino acids from FIV or Visna
mutants 598–601 LGIW/MQEL 1 604–608 SGKL/NQN-
FF and 598–601 LGIW/YQELD 1 604–608 SGKL/
HYQHY, respectively), a more profound impairment of
nvelope processing (9–15% processing) can be ob-
erved (Figs. 4C and 4D). Therefore, these data demon-
trate that replacement of the entire domain located
etween the two Cys residues within HIV-1 MIR with the
orresponding domain from other lentiviruses affects env
rocessing. Furthermore, and as shown above for other
utants, amino acid substitutions in the vicinity of the
wo Cys residues can severely impair the processing of
he precursor glycoprotein.
Altogether the results described above provide further
vidence of the key role played by the HIV-1 MIR domain
n the processing of the precursor glycoprotein (Dedera
T
Effect of Mutations within HIV-1 MI
Construct Assay 1 2 3
NL4-3 p24b 1.35 3.89 5.3
GFPc 1
synd 6
NL4-3[p83-19] p24 0.24 0.129 1.48
GFP —
Syn —
NL4-3[604-606
SGK/GAR] p24 1.47 1.29 0.64
GFP —
Syn —
NL4-3[604-608
SGKLI/TGRIL] p24 0.70 0.70 0.64
GFP —
Syn —
NL4-3[D594-600] p24 0.47 0.93 0.41
GFP —
Syn —
NL4-3[D603-609] p24 1.17 0.41 0.36
GFP —
Syn —
ontrol vector p24 0.35 0.24 0.13
GFP —
Syn —
o DNA control p24 0.13 0.19 0.19
GFP —
Syn —
a CEM-GFP cells were transferred to new flask after sample taken o
b HIV p24 antigen capture assay, ng/ml.
c Cells expressing GFP: 60–5%, 15–30%, 1130–70%, 111.70%.
d Presence of syncytia: 6, a few that were small; 1, large and num
e Percentage of GFP-positive expressing cells as determined by fluot al., 1992; Pancino et al., 1995; Syu et al., 1991) and
ndicate that it is possible to introduce precise modifica-
ions between the two conserved Cys residues within
IR without affecting the processing of the envelope
recursor or the incorporation of gp120 and gp41 into
oninfectious HIV-1-like particles.
Influence of mutations within HIV-1 MIR on infectivity
nd syncytium formation. To further assess functional
roperties associated with mutant gp41 glycoproteins in
he context of infectious HIV-1 particles, we cloned DNA
ncoding selected mutant gp41 glycoproteins into the
nfectious molecular clone pNL4-3 and transfected HeLa
ells with the resultant mutant plasmid vectors. The
ransfected cells were cocultivated with CEM-GFP cells,
nd the percentage of GFP-positive cells and the forma-
ion of syncytia were recorded for 21 days following the
ransfections. As indicated in Table 1, only those cells
hat were transfected with pNL4-3 or pNL4-3-based ex-
ression plasmids containing the envelope gene from
ither the control p83-19 vector or its two mutant deriv-
tives, (604–606 SGK/GAR) and (604–608 SGKLI/TGRIL),
fectivity and Syncytium Formation
of cocultivation with CEM-GFP (day)
5 6 8 14a 16 21
4.91 3.82 3.7 3.99 9.39 3.77
30%e 111 6
1 6
0.19 2.2 4.1 6.31 3.45 8.7
0.15%e 1 11
1 1
0.70 1.17 2.55 2.41 1.25 2.03
0.12%e 6 1
6 —
1.05 2.5 0.747 0.74 1.05 1.50
0.04e 6 1
6 6
0.70 0.27 0.37 0.31 0 0.38
0%e — —
— —
0.36 0.36 0.15 0.16 0.238 0.375
0%e — —
— —
0.13 0.00 0.00 0.00 0.00 0.00
0%e — —
— —
0.13 0.00 0.01 0.00 0.00 0.00
0%e — —
— —
8.
t activated cell sorting.ABLE 1
R on In
Time
4
4.4
11
6
0.02
6
6
6.4
6
—
1.00
6
6
1.05
—
—
0.36
—
—
0.13
—
—
0.13
—
—
n day
erous.
rescen
g
e
6
f
t
6
e
i
s
t
d
a
t
e
p
w
l
i
t
c
H
s
w
t
s
v
d
f
i
n
s
a
n
g
l
p
H
s
i
t
G
o
l
w
d
g
s
o
a
g
d
o
n
e
s
n
i
t
s
n
M
c
i
e
d
n
n
p
i
(
o
a
1
t
m
t
o
t
n
443ANTIGENICALLY MARKED NONINFECTIOUS HIV-1-LIKE PARTICLESave rise to syncytia and activated the LTR-mediated
xpression of GFP. This was particularly evident at days
and 21 posttransfection. However, HeLa cells trans-
ected with the pNL4-3-based expression plasmids con-
aining the envelope gene from deletion mutants (D594–
00) and (D603–609) did not form syncytia or elicit GFP
xpression when cocultivated with CEM-GFP cells. The
nfectivity of the various mutant clones was also as-
essed by measuring p24 levels in the culture superna-
ants, and the results obtained are consistent with those
escribed above for the formation of syncytia. Therefore,
s expected, these data indicate that only HeLa cells
ransfected with constructs that express a processed
nvelope glycoprotein can maintain the fusogenic ca-
acity of the env glycoprotein.
Reactivity of serum from HIV-1-infected individuals
ith synthetic peptides representing wild-type or se-
ected mutated MIR domains. To gain insight on whether
mmunogens incorporating gp41 glycoproteins with mu-
ant MIR domains could potentially be used as vaccine
andidates that allow vaccinees to be distinguished from
IV-1 infectees, we determined by ELISA the reactivity of
ome peptides mimicking specific mutant MIR domains
ith a panel of sera from HIV-1 infectees. We selected
wo peptides representing the GAR and AFR mutants
ince HIV-1-like particles incorporating such mutant en-
elope glycoproteins represent potential vaccine candi-
ates. As shown in Fig. 5, while a large panel of sera
rom HIV-1 infectees reacted with the peptide represent-
ng the MIR domain, none of the sera analyzed recog-
ized the peptides mimicking mutated MIR. The three
amples from HTLV I/II infectees, which served as neg-
tive controls, did not react with any of the peptides (data
ot shown). Therefore, these data suggest that immuno-
ens incorporating these types of gp41 mutants would
ikely not elicit immune responses cross-reacting with
eptides mimicking the immunodominant domain of
IV-1, which are used to screen for HIV-1 seroconver-
ion. To test this hypothesis, mice and guinea pigs were
mmunized with noninfectious HIV-1-like particles con-
aining modified gp41 glycoproteins incorporating the
AR and AFR mutations. Table 2 summarizes the results
btained with guinea pig sera collected 2 weeks after the
FIG. 5. Reactivity of serum from HIV-1-infected individuals with syn-
hetic peptides representing wild-type or selected mutated MIR do-
ains. ELISA plates were coated with synthetic peptides, washed
horoughly, and reacted against serum samples tested at a final dilution
f either 1/10 or 1/50 at room temperature. Serum samples giving rise
o an optical density (450 nm) greater than twofold of that obtained with
ormal human sera were scored positive.ast booster immunization (similar results were obtained
ith three groups of six mice each; data not shown). We
emonstrate that while sera obtained from the four
uinea pigs immunized with wild-type particles (p83-19)
trongly reacted with the MIR peptide, no reactivity was
bserved with any of the sera obtained from the eight
nimals immunized with virus-like particles containing
p41 incorporating the GAR and AFR mutations. We also
emonstrate that this was not due to a deleterious effect
f the introduction of these mutations on the immunoge-
icity of the envelope glycoproteins since similar anti-
nv, as well as anti-gag, immune responses were ob-
erved with all the samples. Furthermore, when HIV-1
eutralizing activity was evaluated by determining fusion
nhibition titers, no differences were observed among the
hree groups of animals. Therefore, these data demon-
trate that, at least for the GAR and AFR mutations,
oninfectious HIV-1-like particles with mutations in the
IR domain represent potential vaccine candidates that
ould allow vaccinees to be distinguished from HIV-1
nfectees.
DISCUSSION
A major challenge in the development of a new gen-
ration of more complex recombinant AIDS vaccine can-
idates incorporating several viral antigens is the engi-
eering of potential antigenic markers that allow vacci-
ees to be distinguished from HIV-1 infectees. We have
reviously demonstrated that mammalian cells can be
TABLE 2
Antibody Responses to Viral Glycoproteins and Determination
of HIV-1 Neutralizing Antibodies
Serum sample Construct
Fusion
inhibitiona
ELISA titer
(reciprocal dilution)
MIRb rgp120 rp24
114 p83-19 20 1 .62,500 .62,500
115 p83-19 40 1 .12,500 .62,500
116 p83-19 20 1 .62,500 .62,500
118 p83-19 40 1 .62,500 .62,500
133 AFR 20 2 .62,500 .62,500
134 AFR 20 2 .62,500 .62,500
135 AFR 20 2 .62,500 .62,500
136 AFR 40 2 .62,500 .62,500
137 GAR 40 2 .62,500 .62,500
138 GAR 20 2 .62,500 .62,500
139 GAR 40 2 .62,500 .62,500
140 GAR 40 2 .62,500 .62,500
a The fusion inhibition titer is the reciprocal of the dilution of the
mmune serum that reduces the number of syncytial foci by 90%
Rovinski et al., 1995).
b A negative (2) score indicates an optical density (450 nm) equal to
r lower than that obtained with prebleed guinea pig serum (0.1), and
positive score (1) indicates an optical density equal to or greater than
.0 at a final dilution of 1/50.
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444 ROVINSKI ET AL.ngineered to produce noninfectious and immunogenic
IV-1-like particles containing most of the structural viral
ntigens (Haynes et al., 1991; Rovinski et al., 1992, 1995).
hese particles could, therefore, potentially elicit in hu-
an vaccinees antibody responses that are similar to
hose observed during seroconversion following viral
nfection. Since one of the landmarks of seroconversion
n virtually all HIV-1 infectees is the appearance of anti-
odies recognizing the MIR domain within gp41 (Gnann
t al., 1987; Norrby et al., 1987), disruption of this domain
ight represent a strategy to engineer antigenic markers
n gp41-containing immunogens. Therefore, as a first
tep toward achieving this goal, we tested in this study
he feasibility of introducing mutations within and in the
icinity of MIR to evaluate whether HIV-1-like particles
ncorporating mutant gp41 glycoproteins could be ex-
ressed in mammalian cells.
To establish whether deletions within MIR would affect
he expression and incorporation of processed env gly-
oproteins into HIV-1-like particles, we engineered three
NA expression constructs in which sequences encod-
ng different portions within or in the vicinity of the im-
unodominant region, delineated by amino acids 598–
09 (LGIWGCSGKLIC), were deleted. Transfection of the
hree plasmid constructs into COS-7 cells resulted in the
roduction of HIV-1-like particles containing primarily
nprocessed env glycoproteins. Therefore, deletions
ithin or adjacent to MIR severely impair gp160 process-
ng. A likely explanation for these observations for two of
he three mutants is that the conserved Cys residues
ere deleted, and previous studies have demonstrated
hat these residues are essential for the processing of
he env glycoproteins of HIV-1 and FIV (Dedera et al.,
992; Pancino et al., 1995; Syu et al., 1991). However,
mino acids within and/or in the proximal vicinity of MIR
nd outside of the domain defined by the two proximal
ys residues also seem to be important for the process-
ng of the precursor glycoprotein as suggested by the
esults obtained with the D594–600 mutant. Therefore, it
s plausible that the conformational integrity of MIR is
rucial for the retention of a particular conformation of
he precursor env glycoprotein that is essential for the
aturation process. In fact, a previous report demon-
trated that a chimeric envelope glycoprotein in which
he major immunodominant region of FIV was replaced
ith that of HIV-1 was processed and retained functional
roperties (Pancino et al., 1995), suggesting that the
tructural integrity of the env precursor rather than just
he amino acid sequence of MIR plays an important role
n the maturation process.
In contrast to the findings described above, we ob-
erved that several amino acid substitutions could be
ntroduced between the two conserved Cys residues of
IR without affecting processing of the precursor env
lycoprotein and incorporation of the mature glycopro-
eins into secreted HIV-1-like particles. In particular, itas observed that the locus defined by amino acids
04–606 (SGK) can tolerate several amino acid substitu-
ions, including nonconserved amino acid replacements.
his particular locus, therefore, represents a potential
arget for mutations that can lead to the development of
p41-containing immunogens with antigenic markers. To
urther evaluate this possibility, two synthetic peptides
ncorporating, respectively, two of the mutations (604–
06 SGK/GAR and 604–606 SGK/AFR) were used to as-
ess their reactivity with a panel of sera from HIV-1
nfectees. Interestingly, while the wild-type peptide was
ecognized by all the sera, the two mutant peptides did
ot react with any of the samples tested. In a study
valuating the viral infectivity of FIV constructs with mu-
ations within MIR, it was also observed that peptides
imicking some of the mutations introduced within this
omain of FIV did not react with sera from infected cats
Pancino and Sonigo, 1997). Therefore, altogether, these
ata provide further support for the development of non-
nfectious HIV-1-like particles containing gp41 with mu-
ations within MIR as potential vaccine candidates. This
s strengthened by the data we obtained from immuno-
enicity studies that demonstrated that, at least for the
AR and AFR mutations, noninfectious HIV-1-like parti-
les with mutations in the MIR domain represent vaccine
andidates that could allow vaccinees to be distin-
uished from HIV-1 infectees.
Since, as shown for HIV-1, the transmembrane glyco-
rotein of several lentiviruses contain a MIR domain
haracterized by the presence of two proximal Cys res-
dues separated by a few amino acids, it was of interest
o determine whether these domains could be used as
ntigenic markers when expressed in the context of a
himeric env glycoprotein. As previously pointed out,
thers have demonstrated the feasibility of expressing
unctional chimeric lentiviral env glycoproteins in which
he amino acids bound by the two Cys residues within
he MIR of FIV were replaced by the corresponding
mino acids from HIV-1 gp41 (Pancino et al., 1995). Our
esults indicated that although not completely impaired,
he processing of chimeric HIV-1 env glycoproteins con-
aining the amino acids bound by the Cys residues of
ither FIV or Visna was affected. These results, at least
ith respect to the chimeric HIV-1/FIV construct, support
he findings described by Pancino et al. (1995). However,
he same authors could not demonstrate expression of
ully processed and functional chimeric FIV/Visna env
lycoproteins. This discrepancy might be partly ex-
lained by the fact that, as suggested in that particular
tudy, while the Visna sequence introduced in an FIV
ackground might confer an unfavorable conformation
or MIR, the presence of the same sequence in an HIV-1
ackground might not result in such unfavorable confor-
ational changes. Interestingly, however, we noticed
hat when in addition to amino acids 604–608, other
esidues within HIV-1 MIR (amino acids 598–601) are
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445ANTIGENICALLY MARKED NONINFECTIOUS HIV-1-LIKE PARTICLESlso replaced with the corresponding residues from FIV
r Visna, a more profound impairment of env processing
an be observed. These results confirm those described
bove for one of the three deletion mutants (D594–600),
nd altogether they suggest that the conformational in-
egrity of MIR plays an important role in the processing of
he precursor env glycoprotein.
Finally, when infectivity studies were carried out with
elected mutants to further assess functional properties
ssociated with mutant gp41 glycoproteins, it was dem-
nstrated that only those chimeras of the infectious mo-
ecular clone pNL4-3 and mutant constructs that con-
ained the genes encoding mutant and poorly processed
lycoproteins were not infectious as judged by syncytia
ormation and release of gag p24. The results from these
unctional studies are in agreement with the fact that
ndoproteolytic cleavage of the HIV-1 precursor env gly-
oprotein is required for viral infectivity (McCune et al.,
988).
In conclusion, we have shown that several amino acid
ubstitutions can be introduced between the two con-
erved Cys residues of HIV-1 MIR without impairing the
rocessing of the precursor env glycoprotein and the
ncorporation of the mature glycoproteins into secreted,
oninfectious HIV-1-like particles. Furthermore, a spe-
ific locus within gp41, defined by amino acids 604–606,
as identified as a target for insertion of antigenic mark-
rs and development of potential vaccine candidates
hat may allow vaccinees to be distinguished from HIV-1
nfectees. In addition to providing the means for distin-
uishing vaccinees from infectees, the insertion of anti-
enic markers within MIR might also provide further
dvantages from a safety standpoint. For example, it has
een shown that some human antibodies directed to
IR enhance HIV-1 infection in vitro (Robinson et al.,
991) while others cross-react with human astrocytes
Spehar and Strand, 1994). Also, one study suggested
hat antibody reactivity to the immunodominant region
ithin the transmembrane glycoprotein of caprine arthri-
is encephalitis virus is associated with development of
rthritis (Bertoni et al., 1994). Therefore, we suggest that
oninfectious HIV-1-like particles incorporating mutant
p41 glycoproteins containing antigenic markers in-
erted within HIV-1 MIR represent potential AIDS vaccine
andidates.
MATERIALS AND METHODS
Cell lines and tissue culture. Monkey kidney COS-7
nd Vero cells were grown and passaged biweekly in
ulbecco’s modified Eagle’s medium (DMEM; Flow Lab-
ratories, McLean, VA) supplemented with 10% heat-
nactivated fetal bovine serum (Bockneck), glutamine (2
M), penicillin (50 IU/ml), and streptomycin (50 mg/ml).
eLa cells were grown and passaged biweekly in
MEM, 10% heat-inactivated fetal bovine serum, glu-amine (2 mM), penicillin (50 IU/ml), and streptomycin (50
g/ml) (Gibco BRL, Grand Island, NY).
Antibodies. An anti-HIV-1 p24 mouse monoclonal an-
ibody (NEA-9306) was obtained from DuPont Canada,
nc. (Markham, Ontario). The anti-gp120MN monoclonal
ntibody 50.1 was obtained from Repligen Corp. (Cam-
ridge, MA). Anti-gp41 monoclonal antibody was purified
rom the Chessie 8 hybridoma (Chessie 8 hybridoma
ells were obtained from G. Lewis through the AIDS
esearch and Reference Reagent Program).
Construction of DNA expression vectors. The nucleo-
ide and amino acid numbering used throughout for
IV-1 was designated by Myers et al. (1990). All expres-
ion vectors were constructed from plasmid p83-19 (Fig.
), which was derived from plasmid pMTHIVd25 (Rovin-
ki et al., 1992) and was engineered to incorporate sev-
ral mutations to enhance safety (Persson et al., 1998).
hese mutations include (1) deletion of both HIV-1 LTRs
nd of a 25-bp DNA fragment (nucleotides 753 to 777;
AI sequence) containing viral RNA packaging se-
uences (Aldovini and Young, 1990; Lever et al., 1989); (2)
wo point mutations in the gag gene to modify the Cys-
is motifs that also play a role in RNA packaging (Dorf-
an et al., 1993; Gorelick et al., 1990); and (3) deletion of
ost of the pol gene to eliminate reverse transcriptase
nd integrase enzyme activities. In this vector, the tran-
cription of the HIV-1 coding sequences is regulated by
he inducible human MT IIa promoter and an SV40 poly-
denylation sequence. A series of p83-19-based expres-
ion vectors encoding env glycoproteins with mutations
ithin or in the vicinity of the MIR of gp41 (residues
98–609) was generated by oligonucleotide-directed
ite-specific mutagenesis using a commercially avail-
ble kit (Amersham Canada Ltd., Oakville, Ontario). To
his end, a 2.7-kbp SalI–BamHI DNA fragment from
83-19 containing the entire env gene coding sequences
as subcloned into M13mp18 prior to mutagenesis. All
utations were confirmed by dideoxy DNA sequencing
n a Prism ABI 377 DNA sequencer (Applied Biosystems,
oster City, CA).
Isolation of HIV-1 virus-like particles. COS-7 cells were
rown to 80% confluence and transfected with 25 mg of
lasmid DNA by the Transfinity (Gibco BRL) calcium
hosphate procedure. Cells were induced 36 h after
ransfection with 5 mM CdCl2 for 12 to 16 h, and culture
edia were then collected and clarified by centrifugation
t 2000 g (Sorvall RT 6000B; DuPont Co., Wilmington, DE)
or 15 min at 4°C. Virus-like particles were pelleted and
solated by ultracentrifugation at 100,000 g using a 20%
lycerol cushion as previously described (Rovinski et al.,
992).
Immunoblot analysis of env glycoproteins associated
ith pelleted HIV-1-like particles. Pelleted virus-like par-
icles were suspended in 40 ml of TNE buffer (10 mM
ris–HCl, pH 8.0, 100 mM NaCl, and 1 mM EDTA), mixed
ith 10 ml of 53 Laemmli sample buffer (Laemmli, 1970),
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446 ROVINSKI ET AL.nd boiled for 3 min. Viral proteins were then separated
y SDS–PAGE and transferred to Immobilon membranes
Millipore, Bedford, MA) (Towbin et al., 1979). Mem-
ranes were blocked with Blotto buffer (PBS containing
% Carnation instant nonfat dry milk, 0.0001% w/v
himerosol, and 0.01% v/v Antifoam A emulsion) for 2 h at
5°C and then incubated overnight at 4°C with either the
eutralizing anti-HIV-1MN gp120 monoclonal antibody
0.1 or the anti-gp41 mouse monoclonal antibody se-
reted by the Chessie 8 hybridoma. Filters were then
ncubated with a goat anti-mouse IgG antibody conju-
ated to alkaline phosphatase (Promega, Madison, WI)
nd reacted with the alkaline phosphatase chromogenic
ubstrates nitroblue tetrazolium chloride and 5-bromo-4-
hloro-3-indolylphosphate p-toluidine salt (Gibco BRL).
Densitometry scanning analysis of immunoblots. West-
rn blots were scanned on a Bio-Rad GS-670 Imaging
ensitometer, and data were analyzed with the Bio-Rad
olecular Analyst software package (Bio-Rad, Hercules,
A).
Source of human serum samples. A total of 63 samples
f serum from individuals infected either with HIV-1 or
TLV-I/II were used to determine their reactivity, as as-
ayed by ELISA, against selected peptides mimicking
ome of the gp41 mutations within MIR. These samples
ncluded 23 sera from HIV-1-infected individuals and
tored frozen at Duke University, 37 HIV-1 sero-positive
amples obtained from the Canadian Red Cross as a
onsequence of their blood donor screening program,
nd 3 HTLV-I-positive serum samples that have been
reviously described (Dekaban et al., 1994). The last
ource included one serum sample from an HTLV-I-
nfected but asymptomatic individual and 2 serum sam-
les from individuals with HTLV-I-associated myelopa-
hy/tropical spastic paraparesis. A Canadian HTLV-II se-
opositive and PCR-positive sample was also tested.
Peptide ELISA assays. Some of the human serum
amples and the guinea pig immune sera were analyzed
s previously described (Graham et al., 1993; Rovinski et
l., 1992). Serum samples obtained from the Canadian
ed Cross, however, were analyzed using a slightly dif-
erent protocol. ELISA plates (Immulon 2, Dynatech Lab-
ratories Inc., West Sussex, UK) were coated with syn-
hetic peptides dissolved in CBC Buffer (35 mM NaHCO3,
5 mM Na2CO3) at 40 mg/ml by overnight incubation at
°C. The plates were then blocked in 3% BSA in 0.1%
BC buffer. The ELISAs were performed essentially as
reviously described (Ford et al., 1992). Briefly, the pep-
ide-coated plates were washed in wash buffer (0.9%
BS, 0.05% Tween 20) three times followed by a wash
ith water. Next, 200 ml of sera diluted 1/50 in serum
iluent (PBS, 0.05% Tween-20, 5% normal goat serum, 2%
owdered milk) was incubated for 90 min at room tem-
erature or overnight at 4°C, washed as above, incu-
ated with 100 ml of a 1/5000 dilution of horseradish
eroxidase-conjugated goat anti-human IgG (Cappel/Or-anon Teknika, Durham, NC) in serum diluent for 60 min
t room temperature, and finally washed again as above.
he TMB detection reagents A and B (KPL, TMB Micro-
ell Peroxidase Substrate System, Gaithersburg, MD)
ere mixed in equal volumes, and 100 ml was added to
ach well, gently mixed, and incubated in the dark for 30
in. The reaction was stopped with 100 ml of 1 M
hosphoric acid and mixed, and the plates were read at
50 nm using the Molecular Devices ELISA plate reader
nd the Softmax analysis package (Menlo Park, CA).
Infectivity and syncytium formation assays. The enve-
ope coding sequences from the wild-type p83-19 and
elected mutant constructs (604–606 SGK/GAR; 604–608
GKLI/TGRIL; D594–600; D603–609) were cloned into the
nfectious molecular clone pNL4-3 (Adachi et al., 1986),
hich was obtained from the AIDS Research and Refer-
nce Reagent Program. To this end, a 2.7-kbp SalI–
amHI DNA fragment containing the entire env gene
oding sequences from either p83-19 or the selected
utant constructs was subcloned into pNL4-3 previously
igested with SalI and BamHI. Subconfluent HeLa cells
n six-well plates (Nunc, Gibco BRL) were transfected
ith 2 mg of each plasmid construct. Transfections were
arried out using 8 ml of Lipofectamine reagent (Gibco
RL) according to the manufacturer’s instructions. The
ext day, the medium was changed and 1 3 106 CEM-
FP cells [GFP gene under the control of an HIV LTR
Gervaix et al., 1997); cells were obtained from the AIDS
esearch and Reference Reagent Program] were added
o each well. Each well was then observed for the for-
ation of syncytia and the expression of GFP using an
xiovert 25 inverted fluorescence microscope (Zeiss Em-
ix Imaging Inc., Mississauga, Ontario, Canada) with a
ercury arc lamp (100 W) and a FITC filter set (consisting
f a 480/40-nm excitation and a 535/50-nm emission
ilter). In addition, a sample of culture supernatant was
emoved, centrifuged to remove cells, and frozen at
80°C until testing in an HIV p24 antigen capture assay
SAIC, Frederick, MD). Alternatively, the day after the
ransfection, medium was changed and the HeLa cells
ere left for 72 h before a sample was removed for HIV
24 antigen capture, at which point CEM-GFP cells were
dded to each well of transfected cells, and monitoring
or syncytia, GFP expression, and HIV p24 antigen was
arried out as described above. In the representative
xperiment presented here, one time point sample of
ocultivated CEM-GFP cells was analyzed to determine
he exact percentage of GFP-positive expressing cells.
his was carried out on a FACSCalibur (Becton Dickin-
on, San Jose, CA). Green fluorescence was measured
hrough a 530-nm/30-nm bandpass filter after illumina-
ion with the 499-nm line of an argon laser. Mock-trans-
ected CEM-GFP cells served as a negative control for
ackground fluorescence.
Immunogenicity studies. HIV-1-like particles were iso-
ated as described above from supernatants of cells
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447ANTIGENICALLY MARKED NONINFECTIOUS HIV-1-LIKE PARTICLESransfected with either the p83-19 (wild-type) vector or
he mutant constructs GAR and AFR. Guinea pigs were
mmunized subcutaneously with purified virus-like parti-
les corresponding to 20 mg of p24 antigen emulsified in
reund’s complete adjuvant. Animals were further
oosted with doses corresponding to 10 mg of p24 anti-
en emulsified in Freund’s incomplete adjuvant every 3
eeks. Blood was collected 14–16 days after each im-
unization. The reactivity of immune sera to the MIR
eptide was evaluated as described above for human
era, and the presence of antibodies to HIV-1 env and
ag proteins was determined as previously described
Rovinski et al., 1992). The neutralizing capacity of the
nimal sera was assessed by a fusion inhibition assay
Rovinski et al., 1995).
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